Infectious Diseases Biomarker Testing Market is Expected to Grow at a CAGR of 15.0% by 2027

Infectious Diseases Biomarker Testing Market is projected to grow at high rate due to increase in government spending in research & development in biomarker testing procedure.The Global Infectious Diseases Biomarker Testing Market was valued at USD 5.1 Bn in 2020 and is expected to reach USD 13.5 Bn by 2027, with a growing CAGR of 15.0% during the forecast period

Epidemiological outbreak of infectious diseases such as coronavirus, ebola, zika, and swine flu creates an opportunity for early diagnosis and prevention of diseases. Such infectious diseases pave the way for demand for point-of-care diagnosis and treatment to fight against such infectious diseases.  

The factors influencing the growth of global infectious diseases biomarker testing market include increase in demand for molecular therapies, rise in research and development facilities and growing prevalence for chronic infectious diseases such as tuberculosis and coronavirus. Moreover, rapid growth in healthcare spending in terms of government initiatives fuels the growth of the infectious diseases’ biomarker testing market. Rise in demand for personalized medicines, rise in demand for innovative diagnostics procedures and developing R&D infrastructure thrives the growth of infectious diseases biomarker testing market.

Infectious diseases biomarker testing system market is broadly segmented into product, application, technology, and region. Based on product, assays hold maximum market share due to increase in one time use diagnostic practice. Based on application, blood stream and hospital acquired infection hold the largest share in infectious diseases biomarker testing market due to increase in rate of hospital- based infections. Based on technology, PCR dominated the infectious diseases biomarker testing market in 2020 and is expected to witness same dominance during the forecast period.

Global Infectious Diseases Biomarker Testing Market by Region Outlook (Revenue, USD Million, 2021-2027)

• North America
• Europe
•  Asia Pacific
•  Latin America
• Middle East & Africa

Based on region, North America held maximum market share in 2020 about 35% due to high prevalence of chronic infectious diseases, high diagnostic rate, and rise in research practices in terms of molecular testing. Increase in government spending in healthcare, rise in disposable income and growing demand for genetic-based research fuels the growth of the infectious diseases’ biomarker testing market across the globe.

The Global Infectious Diseases Biomarker Testing Market Segmentation:

Global Infectious Diseases Biomarker Testing Market by Product Type Outlook (Revenue, USD Million, 2021-2027)

• Assay
• Platforms

Global Infectious Diseases Biomarker Testing Market by Application Type Outlook (Revenue, USD Million, 2021-2027)

• Respiratory Infection
• Bloodstream and Hospital-Acquired Infection
• Sexually Transmitted Infection
• Gastro-Intestinal Infection
• Urinary Tract Infection
• Central Nervous System Infection
• Other

Global Infectious Diseases Biomarker Testing Market by Technology Type Outlook (Revenue, USD Million, 2021-2027)

• PCR
• ELISA or EIA
• NGS
• IHC
• ISH
• Others

Key Findings:

• Based on product, assays product segment accounted for the highest market share in 2020 and expected to increase more during forecast period
• Based on application, blood stream and hospital acquired infection hold the largest share in infectious diseases biomarker testing market due to increase in rate of hospital- based infections
• Based on technology, PCR accounted for the largest share in infectious diseases biomarker testing market in 2020 due to its high demand for diagnosis of various infectious diseases such as covid-19 and viral flu
• Based on region, North America held the maximum market share in 2020 due to high number of infectious patients, local presence of key market players, and demand for early diagnostics

Company Profiles and Competitive Intelligence

The key players operating in the infectious diseases biomarker testing market are:

• Abbott Laboratories
• Agilent Technologies, Inc.
• Becton, Dickinson and Company
• bioMrieux SA
• Bio-Rad Laboratories, Inc.
• Danaher Corporation
• F. Hoffmann-La Roche Ltd
• Hologic, Inc.
• PerkinElmer, Inc.
• QIAGEN N.V.
• Thermo Fisher Scientific, Inc.
• Seegene Inc
•  Co-Diagnostics, Inc.
•  ELITechGroup
• Epitope Diagnostics, Inc

Recent News:

• In May 2019, MeMed developed host based Dx called MeMed BV for differentiating bacterial from viral infections using MeMed Key, a measurement platform with central lab precision. This tool is aimed to provide information to the clinicians for further treatment.
• In March 2020, Abbott launched the fastest molecular point-of-care test for the detection of novel coronavirus by delivering positive results in 15 minutes. The test is aimed to run on company’s ID NOW platform, provided rapid results.